Eric I. Tsao

Suzhou Industrial Park
Suzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Structural basis for broad neutralization of rabies virus by an antibody cocktail SYN023.

Structural basis for broad neutralization of rabies virus by an antibody cocktail SYN023.

Journal: Emerging microbes & infections

Published: August 19, 2025

Validation of the Rapid Fluorescent Focus Inhibition Test for Rabies Virus Neutralizing Antibodies - China, 2025.

Validation of the Rapid Fluorescent Focus Inhibition Test for Rabies Virus Neutralizing Antibodies - China, 2025.

Journal: China CDC weekly

Published: July 17, 2025

The efficacy and safety of SYN023 (Zamerovimab and Mazorelvimab injection), the recombinant humanized anti-rabies virus monoclonal antibody mixture, combined with rabies vaccine in a WHO category III rabies post-exposure population: A randomized, double-blind, positive control, phase III clinical trial.

The efficacy and safety of SYN023 (Zamerovimab and Mazorelvimab injection), the recombinant humanized anti-rabies virus monoclonal antibody mixture, combined with rabies vaccine in a WHO category III rabies post-exposure population: A randomized, double-blind, positive control, phase III clinical trial.

Journal: Vaccine

Published: February 24, 2025

The pharmacokinetics and safety comparison of Zamerovimab and Mazorelvimab monoclonal antibodies vs. HRIG in category III rabies post-exposure prophylaxis: a stratified analysis by wound characteristics.

The pharmacokinetics and safety comparison of Zamerovimab and Mazorelvimab monoclonal antibodies vs. HRIG in category III rabies post-exposure prophylaxis: a stratified analysis by wound characteristics.

Journal: Biologicals : journal of the International Association of Biological Standardization

Published: December 15, 2024

A phase 2b, Randomized, double blinded comparison of the safety and efficacy of the monoclonal antibody mixture SYN023 and human rabies immune globulin in patients exposed to rabies.

A phase 2b, Randomized, double blinded comparison of the safety and efficacy of the monoclonal antibody mixture SYN023 and human rabies immune globulin in patients exposed to rabies.

Journal: Vaccine

Published: March 29, 2024

Preclinical Pharmacokinetics and Biodistribution of LR004, a Novel Antiepidermal Growth Factor Receptor Monoclonal Antibody.

Preclinical Pharmacokinetics and Biodistribution of LR004, a Novel Antiepidermal Growth Factor Receptor Monoclonal Antibody.

Journal: Molecules (Basel, Switzerland)

Published: December 08, 2023

Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial.

Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial.

Journal: Vaccine

Published: May 10, 2021

Safety, Pharmacokinetics, and Neutralizing Activity of SYN023, a Mixture of Two Novel Antirabies Monoclonal Antibodies Intended for Use in Postrabies Exposure Prophylaxis.

Safety, Pharmacokinetics, and Neutralizing Activity of SYN023, a Mixture of Two Novel Antirabies Monoclonal Antibodies Intended for Use in Postrabies Exposure Prophylaxis.

Journal: Clinical pharmacology in drug development

Published: September 17, 2020

Safety, pharmacokinetics and pharmacodynamics of SYN023 alone or in combination with a rabies vaccine: An open, parallel, single dose, phase 1 bridging study in healthy Chinese subjects.

Safety, pharmacokinetics and pharmacodynamics of SYN023 alone or in combination with a rabies vaccine: An open, parallel, single dose, phase 1 bridging study in healthy Chinese subjects.

Journal: Antiviral research

Published: July 08, 2020

In Vivo Efficacy of SYN023, an Anti-Rabies Monoclonal Antibody Cocktail, in Post-Exposure Prophylaxis Animal Models.

In Vivo Efficacy of SYN023, an Anti-Rabies Monoclonal Antibody Cocktail, in Post-Exposure Prophylaxis Animal Models.

Journal: Tropical medicine and infectious disease

Published: December 30, 2019

SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies.

SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies.

Journal: PLoS neglected tropical diseases

Published: February 21, 2017

Showing 1-11 of 11

Last Updated: 09/26/2026